News & Events
Keep up to date with Isogenica’s latest news on collaborations, Press Releases, Events and VHH antibody resources.
Isogenica’s
Latest News
Why is Cancer so Hard? Marion Cubbitt tells us her thoughts…
Researchers have been trying to fight cancer for over 100 years, yet there’s still no cure. What makes treating cancer so challenging? We asked our Director of Discovery for her views…
Isogenica turns 25: Our journey
We’ve come a long way over the past quarter century, from our early years as a therapeutic peptide discovery company to specialising in VHH antibodies. Here’s the story…
PEGS 2022: Isogenica showcases plans for implementing machine learning tools
As part of our KTP partnership between Aston University and Nottingham University, we’re developing and integrating an ML-assisted pipeline for faster discovery and optimisation of VHH antibodies for next-generation biotherapeutics.
Events
Isogenica are always looking to learn and connect at upcoming events and conferences.
Events
Resources
Due to their unique characteristics, VHH are promising candidates for a range of application areas including intracellular targeting and even across the Blood Brain Barrier (BBB). Discover all the benefits in using VHH in different applications.
Prediction of Antibody-Antigen Binding via Machine Learning: Development of Data Sets and Evaluation of Methods
Published on ScienceDirect, this paper analyses machine-learning approaches to antibody–antigen binding. It evaluates datasets and early ML methods for predicting antibody specificity directly from sequence, outlining key limitations and opportunities for scalable, sequence-based binding prediction.
IgBlend: Unifying 3D Structures and Sequences in Antibody Language Models
A recent bioRxiv preprint examines structure-aware antibody language models. IgBlend combines antibody sequences with 3D structural coordinates, improving sequence recovery, CDR editing and inverse folding, with model likelihoods correlating with experimental binding affinity.
Webinars
Webinars are a great source for the latest activities at Isogenica. Hear all about the newest applications of VHH.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Isogenica’s
Newsletters
Catch up with Isogenica’s news and activies through the latest Newsletters.
Using Llama-vhh To Optimize T-cell Mediated Immunotherapies
Listen to Senior Director of Antibody Discovery Dr Ed McGowan and his thorough review of the applications of VHH single domain antibodies in CAR-T and T cell engagers.
Dr Bjorn Cochlovius appointed as Chairman of Isogenica Board of Directors
Isogenica has announced today that Jan-Olof Lundin, Non-Executive Chairman of the Board of Directors (the “Board”) will retire from the Board effective 31 December 2019.
Nature Communications publishes UMC Utrecht and Isogenica research on VHHmediated targeting of LRP5 and LRP6
Under a collaboration between Isogenica and scientists at the Oncode Institute and University Medical Center Utrecht, led by Professor Madelon Maurice, Isogenica’s fully synthetic, highly diverse LlamdA™ library was screened for Wnt pathway inhibitors using CIS Display, the company’s in vitro library selection system.
Isogenica expands collaboration with Aro Biotherapeutics
Under the expanded agreement, Isogenica will use its CIS Display platform to help Aro achieve its goal of developing novel CentyrinsTM against multiple targets for cell specific delivery